Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
F 4.34 -1.81% -0.08
NCNA closed down 1.81 percent on Thursday, April 15, 2021, on 58 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical NCNA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -1.81%
Oversold Stochastic Weakness -1.81%
New 52 Week Closing Low Bearish 0.70%
Lower Bollinger Band Walk Weakness 0.70%
Wide Bands Range Expansion 0.70%
Oversold Stochastic Weakness 0.70%
New Downtrend Bearish -0.12%
Older End-of-Day Signals for NCNA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 17 hours ago
Rose Above Previous Day's High about 20 hours ago
Up 2% about 20 hours ago
Up 1% about 20 hours ago
Rose Above Previous Day's High 2 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

NuCana plc Description

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Treatment Of Cancer Health Sciences Cancers Drug Discovery Cancer Cell Solid Tumor Cancers Organofluorides Prodrugs Gemcitabine

Is NCNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.83
52 Week Low 4.1001
Average Volume 249,382
200-Day Moving Average 5.23
50-Day Moving Average 5.31
20-Day Moving Average 4.88
10-Day Moving Average 4.59
Average True Range 0.27
ADX 29.72
+DI 13.27
-DI 31.27
Chandelier Exit (Long, 3 ATRs ) 4.97
Chandelier Exit (Short, 3 ATRs ) 4.96
Upper Bollinger Band 5.67
Lower Bollinger Band 4.09
Percent B (%b) 0.16
BandWidth 32.39
MACD Line -0.27
MACD Signal Line -0.22
MACD Histogram -0.0524
Fundamentals Value
Market Cap 222.1 Million
Num Shares 51.2 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -6.85
Price-to-Sales 0.00
Price-to-Book 1.63
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.60
Resistance 3 (R3) 4.62 4.57 4.55
Resistance 2 (R2) 4.57 4.50 4.55 4.54
Resistance 1 (R1) 4.45 4.46 4.43 4.43 4.52
Pivot Point 4.40 4.40 4.38 4.38 4.40
Support 1 (S1) 4.28 4.33 4.26 4.26 4.16
Support 2 (S2) 4.23 4.29 4.21 4.14
Support 3 (S3) 4.11 4.23 4.13
Support 4 (S4) 4.09